Free Trial

Day One Biopharmaceuticals Q4 2023 Earnings Report

Day One Biopharmaceuticals logo
$7.93 -0.14 (-1.73%)
As of 03/31/2025 04:00 PM Eastern

Day One Biopharmaceuticals EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.57
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Day One Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Remove Ads

Day One Biopharmaceuticals Earnings Headlines

Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
Day One price target lowered to $30 from $34 at JonesResearch
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat